Clinical trials
Observational Primary Immunodeficiency Diseases trials with unknown status
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
18 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2006 | 1 |
| 2012 | 2 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 2 |
| 2020 | 4 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 18 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 2 |
| ADMA Biologics, Inc. | 1 |
| Assistance Publique Hopitaux De Marseille | 1 |
| Beijing Children's Hospital | 1 |
| CHU de Reims | 1 |
| Children's Hospital of Fudan University | 1 |
| Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 1 |
| Gazi University | 1 |
| Hospices Civils de Lyon | 1 |
| Kirby Institute | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Primary Immunodeficiency Diseases | 18 |
| Agammaglobulinemia | 1 |
| Autoimmune Diseases | 1 |
| COVID-19 | 1 |
| Campylobacter Infections | 1 |
| Communicable Diseases | 1 |
| Genetic Diseases, Inborn | 1 |
| Hyper-IgM Immunodeficiency Syndrome, Type 1 | 1 |
| Immune System Diseases | 1 |
| Immunologic Deficiency Syndromes | 1 |
Trials
Showing 1 to 18 of 18. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.